Evolution of liver stiffness and post-treatment surveillance by liver elastography for HCV patients in the DAA era

References

• Bourliere M, Gordon SC, Flamm SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376(22):2134–2146.
   PubMed Web of Science ®Google Scholar
• Piecha F, Ganssler JM, Ozga AK, et al. Treatment and re-treatment results of HCV patients in the DAA era. PLoS One. 2020;15(5):e0232773.
   PubMed Web of Science ®Google Scholar
• Mullhaupt B, Bruggmann P, Bihl F, et al. Progress toward implementing the Swiss hepatitis strategy: is HCV elimination possible by 2030? PLoS One. 2018;13(12):e0209374.
   PubMed Web of Science ®Google Scholar
• Nahon P, Bourcier V, Layese R, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology. 2017;152(1):142–156.e142.
   PubMed Web of Science ®Google Scholar
• Kanwal F, Kramer J, Asch SM, et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 2017;153(4):996–1005.e1001.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Lim JK, Fried MW. American gastroenterological association institute clinical practice update-expert review: care of patients who have achieved a sustained virologic response after antiviral therapy for chronic hepatitis C infection. Gastroenterology. 2017;152(6):1578–1587.
   PubMed Web of Science ®Google Scholar
• de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743–752.
   PubMed Web of Science ®Google Scholar
• Murillo Perez CF, Hirschfield GM, Corpechot C, et al. Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. Aliment Pharmacol Ther. 2019;50(10):1127–1136.
   PubMed Web of Science ®Google Scholar
• Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–397.e310.
   PubMed Web of Science ®Google Scholar
• Vergniol J, Foucher J, Terrebonne E, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology. 2011;140(7):1970–1979, 1979 e1971-1973.
   PubMed Web of Science ®Google Scholar
• EASL-ALEH. Clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;65:692–699.
   Google Scholar
• Serra-Burriel M, Graupera I, Toran P, et al. Transient elastography for screening of liver fibrosis: cost-effectiveness analysis from six prospective cohorts in Europe and Asia. J Hepatol. 2019;71(6):1141–1151.
   PubMed Web of Science ®Google Scholar
• Millonig G, Friedrich S, Adolf S, et al. Liver stiffness is directly influenced by central venous pressure. J Hepatol. 2010;52(2):206–210.
   PubMed Web of Science ®Google Scholar
• Millonig G, Reimann FM, Friedrich S, et al. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology. 2008;48(5):1718–1723.
   PubMed Web of Science ®Google Scholar
• Piecha F, Mandorfer M, Peccerella T, et al. Pharmacological decrease of liver stiffness is pressure-related and predicts long-term clinical outcome. Am J Physiol Gastrointest Liver Physiol. 2018; 315(4):G484–G494.
   PubMed Web of Science ®Google Scholar
• Piecha F, Paech D, Sollors J, et al. Rapid change of liver stiffness after variceal ligation and TIPS implantation. Am J Physiol Gastrointest Liver Physiol. 2018; 314(2):G179– G187.
   PubMed Web of Science ®Google Scholar
• Piecha F, Peccerella T, Bruckner T, et al. Arterial pressure suffices to increase liver stiffness. Am J Physiol Gastrointest Liver Physiol. 2016;311(5):G945–G953.
   PubMed Web of Science ®Google Scholar
• Piecha F, Wiegard C. Beurteilung der leberfibrose. Gastroenterol Up2date. 2019;15(04):355–371.
   Google Scholar
• Mueller S, Englert S, Seitz HK, et al. Inflammation-adapted liver stiffness values for improved fibrosis staging in patients with hepatitis C virus and alcoholic liver disease. Liver Int. 2015;35(12):2514–2521.
   PubMed Web of Science ®Google Scholar
• Hartl J, Ehlken H, Sebode M, et al. Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis. J Hepatol. 2017;68:754–763.
   PubMed Web of Science ®Google Scholar
• Hartl J, Denzer U, Ehlken H, et al. Transient elastography in autoimmune hepatitis: timing determines the impact of inflammation and fibrosis. J Hepatol. 2016;65(4):769–775.
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Del Prete V, Turco A, et al. Long-term liver stiffness assessment in hepatitis C virus patients undergoing antiviral therapy: results from a 5-year cohort study. J Gastroenterol Hepatol. 2018;33(4):942–949.
   PubMed Web of Science ®Google Scholar
• Hsu WF, Lai HC, Su WP, et al. Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents. BMC Gastroenterol. 2019;19(1):63.
   PubMed Web of Science ®Google Scholar
• Singh S, Facciorusso A, Loomba R, et al. Magnitude and kinetics of decrease in liver stiffness after antiviral therapy in patients with chronic hepatitis C: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(1):27–38.e24.
   PubMed Web of Science ®Google Scholar
• Mueller S, Sandrin L. Liver stiffness: a novel parameter for the diagnosis of liver disease. Hepat Med. 2010;2:49–67.
   PubMedGoogle Scholar
• Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43(6):1317–1325.
   PubMed Web of Science ®Google Scholar
• Piecha F, Ganssler JM, Jordan S, et al. Transjugular intrahepatic portosystemic shunt: a possible risk factor for direct-acting antiviral treatment failure in patients with hepatitis C? Hepatol Commun. 2019;3(5):614–619.
   PubMed Web of Science ®Google Scholar
• Pietsch V, Deterding K, Attia D, et al. Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals. United Eur Gastroenterol J. 2018;6(8):1188–1198.
   PubMed Web of Science ®Google Scholar
• George SL, Bacon BR, Brunt EM, et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009;49(3):729–738.
   PubMed Web of Science ®Google Scholar
• Mueller S, Millonig G, Sarovska L, et al. Increased liver stiffness in alcoholic liver disease: differentiating fibrosis from steatohepatitis. World J Gastroenterol. 2010;16(8):966–972.
   PubMed Web of Science ®Google Scholar
• Hedenstierna M, Nangarhari A, El-Sabini A, et al. Cirrhosis, high age and high body mass index are risk factors for persisting advanced fibrosis after sustained virological response in chronic hepatitis C. J Viral Hepat. 2018;25(7):802–810.
   PubMed Web of Science ®Google Scholar
• Mandorfer M, Kozbial K, Schwabl P, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol. 2016;65:692–699.
   PubMed Web of Science ®Google Scholar
• Mandorfer M, Kozbial K, Schwabl P, et al. Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic response to interferon-free therapy. Hepatology 2020;71(3):1023–1036.
   PubMed Web of Science ®Google Scholar
• Pons M, Rodriguez-Tajes S, Esteban JI, et al. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. J Hepatol. 2019;72:472–480.
   PubMed Web of Science ®Google Scholar
• Semmler G, Binter T, Kozbial K, et al. Non-invasive risk stratification after HCV-eradication in patients with advanced chronic liver disease. Hepatology. 2021;73(4):1275–1289.
   PubMed Web of Science ®Google Scholar
• Jansen C, Moller P, Meyer C, et al. Increase in liver stiffness after transjugular intrahepatic portosystemic shunt is associated with inflammation and predicts mortality. Hepatology. 2018;67(4):1472–1484.
   PubMed Web of Science ®Google Scholar
• Anugwom C, Ashraf A, Debes JD. Virus-mediated thrombocytopenia in Hepatitis C infection: the impact on fibrosis scores. Dig Liver Dis. 2020;52(7):797–798.
   PubMedGoogle Scholar